A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastati

• Status: Not yet recruiting
• Trial end date: 2024-12-31

Summary

Aim：Evaluate the efficiency and safety of anti-PD1 antibody (Camrelizumab) combined with Paclitaxel(Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer.

Drug information：

• anti-PD1 antibody (Camrelizumab)

• AG regimens：the standard first-line regimens for metastatic pancreatic cancer.

• Phase: Phase 3

Details

• Lead Sponsor: RenJi Hospital
• Treatments: Gemcitabine; Paclitaxel